Agile Therapeutics, Inc. (AGRX)
OTCMKTS: AGRX · Delayed Price · USD
0.405
-0.035 (-7.90%)
May 2, 2024, 3:50 PM EDT - Market closed
Agile Therapeutics Revenue
In the year 2023, Agile Therapeutics had annual revenue of $19.59M with 80.02% growth. Revenue in the quarter ending December 31, 2023 was $3.61M, a -9.56% decrease year-over-year.
Revenue (ttm)
$19.59M
Revenue Growth
+79.99%
P/S Ratio
0.14
Revenue / Employee
$1,031,158
Employees
19
Market Cap
2.78M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 19.59M | 8.71M | 80.02% |
Dec 31, 2022 | 10.88M | 6.78M | 165.40% |
Dec 31, 2021 | 4.10M | 3.35M | 447.53% |
Dec 31, 2020 | 749.00K | - | - |
Dec 31, 2019 | 0 | - | - |
Dec 31, 2018 | 0 | - | - |
Dec 31, 2017 | 0 | - | - |
Dec 31, 2016 | 0 | - | - |
Dec 31, 2015 | 0 | - | - |
Dec 31, 2014 | 0 | - | - |
Dec 31, 2013 | 0 | - | - |
Dec 31, 2012 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 371.62B |
Johnson & Johnson | 85.16B |
Merck & Co. | 60.12B |
AbbVie | 54.32B |
Novartis AG | 49.92B |
AstraZeneca | 47.61B |
Thermo Fisher | 42.86B |
Abbott Laboratories | 40.11B |
AGRX News
- 5 weeks ago - Agile Therapeutics Reports Fourth Quarter & Full Year 2023 Financial Results and Provides Corporate Update - GlobeNewsWire
- 5 weeks ago - Agile Therapeutics Announces Delisting from Nasdaq - GlobeNewsWire
- 6 weeks ago - Correction - Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 28, 2024 - GlobeNewsWire
- 6 weeks ago - Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Friday, March 22, 2024 - GlobeNewsWire
- 7 weeks ago - Agile Therapeutics Completes Pay-off of Debt and Remains Focused on Business Plan Execution - GlobeNewsWire
- 2 months ago - Agile Therapeutics Announces Exercise of Warrants for $4.8 Million Gross Proceeds - GlobeNewsWire
- 2 months ago - Agile Therapeutics Announces Extension Granted by Nasdaq Hearings Panel to Regain Compliance with the Stockholders' Equity Continued Listing Requirement & Provides Performance Update - GlobeNewsWire
- 3 months ago - The Biden-Harris Administration Announces New Guidance to Enable Expanded Access to All FDA-Approved Contraceptives Without Cost - GlobeNewsWire